Stocktoria
MACROGENICS INC MGNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-10-10
MACROGENICS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -48.7% | -73.7% | -286.4% | -79.9% | -261.9% |
| Net margin | -49.9% | -44.7% | -15.4% | -78.8% | -261.0% |
| FCF margin | -55.5% | -48.1% | -136.1% | -59.6% | -193.7% |
| Return on assets | -29.1% | -25.6% | -3.0% | -42.7% | -60.3% |
| Return on equity | -134.2% | -57.7% | -5.9% | -84.3% | -84.3% |
| Current ratio | 5.10 | 3.92 | 4.48 | 4.57 | 3.75 |
| Revenue growth | -0.3% | 155.3% | -61.3% | 96.2% | -26.2% |
Source: SEC EDGAR filings · CIK 0001125345 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.